ANTX logo

AN2 THERAPEUTICS INC

ANTXNASDAQ
🏆 #3779 by market capEarnings Nov 10US Equity
$5.10▲ $0.06 (+1.09%)
After hours · at close
🔔
Track ANTX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 1.1%
7d▲ 5.3%
14d▼ 4.5%
30d▼ 8.8%
ytd▲ 367.9%
1y▲ 295.3%
🏦Market Cap
$184M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$5.02 – $5.19
52-Week Range
$1.00 – $7.19
Volume
$3.28B
Avg Volume
$3.09B
Shares Outstanding
36.0M
Next Earnings
Dec 16, 2026

Fundamentals Snapshot

Annual Revenue
$20M
Last Q Revenue
$6M
P/E Ratio
-4.7
P/S Ratio
0.0x
EPS (TTM)
$-0.81
Dividend Yield
0.00%
Dilution (1yr)
+1.1%

Why Investors Own ANTX

  • ✓High-growth profile — revenue up +22.1% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 30% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ANTX logo

AN2 THERAPEUTICS INC

ANTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$38M▼ −30.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$30M▼ −39.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.2M▲ +1.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$20M▼ −$1M YoY
StockOtter · stockotter.space

About AN2 THERAPEUTICS INC

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$6.76
▲ +32.6% Upside
High Target$8.14
Low Target$5.21
Based on 35 analysts

Latest News & Updates

🚀
Barron’s·2h ago

AN2 THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift ANTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

AN2 THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.